- Home
- RARE vs BKV Comparison
RARE vs BKV Comparison
Compare RARE & BKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | BKV |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RARE | BKV |
|---|---|---|
| Price | $34.13 | $27.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $85.20 | $30.29 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | $630,598,000.00 | ★ $822,525,000.00 |
| Revenue This Year | $19.09 | $50.73 |
| Revenue Next Year | $20.62 | $43.23 |
| P/E Ratio | ★ N/A | $51.56 |
| Revenue Growth | 20.63 | ★ 33.41 |
| 52 Week Low | $25.81 | $15.00 |
| 52 Week High | $46.50 | $29.65 |
Technical Indicators
Market Signals| Indicator | RARE | BKV |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 56.48 |
| Support Level | $32.64 | $25.63 |
| Resistance Level | $35.12 | $27.29 |
| Average True Range (ATR) | 1.44 | 1.04 |
| MACD | -0.27 | -0.22 |
| Stochastic Oscillator | 22.07 | 58.21 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About BKV BKV Corporation
BKV Corp is a growth-driven energy company. Its core business is production of natural gas from its owned and operated upstream businesses. It operates in four business lines: natural gas production, natural gas gathering, processing and transportation (natural gas midstream business), power generation and carbon capture, utilization, and sequestration (CCUS).